Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2015

Does the Addition of Piracetam Safely and
Effectively Improve Behavioral and or Cognitive
Functions in Schizophrenia?
Dieu Linh Nguyen
Philadelphia College of Osteopathic Medicine, Dieulinhng@pcom.edu

Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Mental Disorders Commons
Recommended Citation
Nguyen, Dieu Linh, "Does the Addition of Piracetam Safely and Effectively Improve Behavioral and or Cognitive Functions in
Schizophrenia?" (2015). PCOM Physician Assistant Studies Student Scholarship. 240.
http://digitalcommons.pcom.edu/pa_systematic_reviews/240

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Does The Addition Of Piracetam Safely And Effectively Improve Behavioral And Or
Cognitive Functions In Schizophrenia?

Dieu Linh Nguyen, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements for
The Degree of Master of Science
In
Health Sciences - Physician Assistant

Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

December 19, 2014

ABSTRACT

OBJECTIVE: The objective of this selective evidence based medicine (EBM) review is to
determine whether or not the addition of piracetam safely and effectively improve behavioral and
or cognitive functions in schizophrenia.
STUDY DESIGN: The selected review from all English language, primary literature sources
that were published between 1979 and 1999.
DATA SOURCES: Three double blind randomized controlled trials (RCT) and one case
controlled clinical study that compared piracetam to a visually matched placebo was selected and
found using Medline, PubMed, Ebscohost, and Cochrane databases.
OUTCOMES MEASURED: Each of the trials assessed the effect of Piracetam on behavioral
and or clinical functions of Schizophrenia patients by utilizing the following assessment tools:
Brief Psychiatric Rating Scale (BPRS), The Behavior Rating Scale, The Wing Symptom Rating,
and Positive and Negative Syndrome Scale (PANSS).
RESULTS: The trials demonstrated that the mean change before treatment with the use of
piracetam as opposed to the visually matched placebo, as compared to after the treatment was
large, with all statistically significant P values ≤ 0.05. This demonstrated that there was
improvement in behavioral and cognitive functions achieved with the treatment of piracetam
versus placebo.
CONCLUSION: Based on the studies, all reported that with the use of piracetam in
schizophrenia, there showed improvement of some type of behavioral and or cognitive functions
above baseline. Although the pattern of outcome was similar in all the studies, there requires a
continued and more updated investigation to be aimed at determining a specific dose of
piracetam therapy, a specific patient population for which piracetam is most effective and to
further elaborate its safety profile outside a controlled research setting.
KEY WORDS: Piracetam, Nootropic Drugs, Psychosis, Psychiatric, Schizophrenia, Behavioral
Functions, Cognitive Functions
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INTRODUCTION
Schizophrenia is a pervasive, debilitating mental disease characterized by positive
symptoms of hallucinations, delusions, and thought disorder (also referred to as psychosis), and
negative symptoms of chronic social dilapidation.1 The exact mechanism of schizophrenia is
unknown although research continues to suggest that both chemical and physical abnormalities
such as excess amounts of neurotransmitter dopamine or unusual chemical balance are associated
with schizophrenia. There are also identifiable risk factors such as increasing parental age, winter
birth, early development insults, migration, and genetic linkages.2 It is observed in ~6.6% of all
first-degree relatives and if both parents are affected, the risk of offspring is 40%.3
On average the incidence of people suffering from schizophrenia annually is 35 per
100,000 in population and there is a 1% prevalence in the world that a person will manifest the
condition during their lifetime, thus making it more common than diabetes, Alzheimer’s disease,
and multiple sclerosis.3 It typically begins in adulthood with the average onset for men between
18-25 years old and women between 25-35 years old.4 Schizophrenic patients makes up almost
30% of new admissions to psychiatric institutions and occupy about half the beds in mental
hospitals.2 There is not an exact number of healthcare admissions each year due to the broad
category of mental illness, however, there is an estimated 300,000 episodes of acute
schizophrenia occurring annually in the United States with costs estimating to be over 50 billion
dollars.5 Therefore, it is crucial that the Physician Assistants or other healthcare providers be able
to identify the condition and initiate treatment for the patients.
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Schizophrenia appears to be a heterogeneous collection of many distinct diseases, which
remain poorly defined but linked by common clinical features. Three major symptom clusters are
seen in schizophrenia: positive, negative, and cognitive symptoms. Positive symptoms include
hallucinations and delusions, experiences that are not characteristic of normal mental life.
Negative symptoms represent deficits in normal functions such as blunted affect, impoverished
speech, asocial behavior, and diminished motivation. Cognitive symptoms include deficits in
working memory and cognitive control of behavior that often prove extremely disabling.6 Some
additional examples of cognitive control of behavior are organizing, problem solving or task
switching. Schizophrenia remains a clinical diagnosis made on the basis of the individual's
psychiatric history and mental status examination, as no laboratory or imaging studies can
validly diagnose it.7 Physician Assistants in primary care may be one of the first providers to
encounter schizophrenia patients, so having knowledge and a high clinical suspicion may help
establish a diagnosis and treatment plan more rapidly.
The general treatments for schizophrenia are atypical antipsychotics used to block
receptors in the brain’s dopamine pathways. They are the cornerstone in acute and maintenance
treatment of schizophrenia. Atypical antipyschotics also known as second generation
antipyschotics include aripiprazole, olanazapine, quetiapine, risperidone, and ziprasidone.8 The
atypical antipsychotic treatment options for schizophrenia all play an effective role on patients
with schizophrenia. However, as with all medications, each option will have a different effect on
each patient. Current general atypical antipsychotic drugs are efficacious for negative symptoms
and cognitive only and generally lack efficacy for positive symptoms.6 For positive symptoms,
typical antipsychotics such as haloperidol, chlorpromazine, and fluphenazine can be used.
However, these drugs have two major drawbacks: it is often difficult to find the best dosage level
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for the individual patient, and a dosage level high enough to control psychotic symptoms
frequently produces extrapyramidal side effects, or EPS.4 Successful treatment of the disorder,
therefore, requires attention not only to psychopathological domains such as positive and
negative symptoms, but also to cognition and functional capacity. Cognitive dysfunction is an
important treatment goal of piracetam. Piracetam is a nootropic drug that improves one or more
aspects of mental functions, predominantly cognitive functions such as working memory,
motivation and attention.8 Piracetam may be used as an oral supplement for the relief of negative
symptoms of schizophrenia and in improving cognitive functions will also improve behavioral
functions. Although treatment with piracetam, used off label, has been shown to improve
cognitive performance in schizophrenia and in other neuropsychological disorders worldwide,
there is still lack of published reports evaluating the effects of the addition of piracetam on
behavioral and cognitive functions in schizophrenia patients in the United States.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not the addition of
piracetam is safe and effective in improving behavioral and or cognitive functions in adults with
schizophrenia.
METHODS
To examine the objective question, this research paper focuses on adults (age ≥ 18 years
old) with a diagnosis of schizophrenia or psychosis. All studies that were considered in the
literature search included interventions of piracetam and a visually matched placebo, provided
that the study had at least one arm including piracetam as an intervention and one without, to
assess behavioral or cognitive functions. Types of studies considered were randomized control
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trials; however, one study that was selected was a case controlled clinical study which includes
data analysis. All patients in the selected articles had similar demographics and characteristics
(Table 1).
Articles that were searched were peer reviewed journal published in the English
language. A detailed search was performed through various search engines that included:
Medline, PubMed, Ebscohost and Cochrane databases. Key words used in the search included:
piracetam, nootropic drugs, schizophrenia, psychosis, psychiatric, behavioral functions, and
cognitive functions. Articles were selected based on their relevance and importance of the
outcome to the patient (Patient Oriented Evidence That Matters, POEMS). Inclusion criteria for
the data sources consisted of double-blinded, placebo controlled RCTs that were the latest
publishing available. Exclusion criteria consists of articles that included medications other than
piracetam, did not compare with a placebo medical conditions aside from psychosis or
schizophrenia, patients under age 18, pregnant, those with a concomitant physical disability, or
having a language barrier. Statistics were then reported based on p-values, mean change from
baseline, ANOVA F-score, relative benefit increase (RBI), absolute benefit increase (ABI),
number needed to treat (NNT), and the following assessment scores: Brief Psychiatric Rating
Scale (BPRS), The Behavior Rating Scale, The Wing Symptom Rating, and the Positive and
Negative Syndrome Scale (PANSS), were used to assess the severity of the psychosis symptoms
and rates them to guide the practitioner’s route of therapy.
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Table 1 - Demographics & Characteristics of included studies
Study

Type

#
Pts

Age
(yrs)

Inclusion Criteria

Exclusion
Criteria

W/D

Intervention

Chouinard
G., Annable
L., RossChouinard
A., Fontaine
F. 198310

RCT

60

54-80

diagnosed as
having
schizophrenia
disorder/affective
schizophrenic
disorder; must
satisfy
psychiatric,
neurologic and
medical criteria

Pts with major
cerebral
impairment or
focal cerebral
lesion/ Pts with a
major physical
illness

1

Piracetam
800 mg 2
tablets TID

Dimond S.,
Scammell R.,
Pryce I.,
Huws D.,
Gray C.
197911

RCT

24

38-63

male and female
suffering from
chronic
schizophrenia; all
patients were
inpatient or
residing in
residential hostel

Concomitant
physical illness,
language
difficulties,
current disturbed
behavior, or
outside
employment

0

Piracetam
800 mg 2
tabs TID

Noorbala A., RCT
Akhondzadeh
S., DavariAshtiani R.,
AminiNooshabadi
H. 199912

34

18-41

Minimum score
of 60 on the
Positive and
Negative
Syndrome Scale
(PANSS)

Significant
organic,
neurological
disorders or
serious psychotic
disorders other
than
schizophrenia;
pregnant or
lactating women
and those of
reproductive age
without adequate
contraception

0

Piracetam
3200 mg/d

Kabes J.,
Erban L.,
Hanzlicek L.,
Skondia V.
197913

14

23-50

Patients suffering
from a functional
psychosis

None stated

0

Piracetam
2400mg q/d

Control
Clinical
Trial
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OUTCOMES MEASURED
The outcomes measured were based off each of the trials assessing the safety and efficacy
of piracetam on several aspects of behavioral and cognitive functions. This included the mean
change from baseline, dichotomous data, ANOVA, and PANSS. In the Chouinard and Kabes’
study, efficacy was assessed with the Brief Psychiatric Rating Scale at mean change from
baseline and conclusion that was also convertible into dichotomous data. Similarly, in the
Noorbala study, efficacy was assessed via the PANSS at baseline and at conclusion looking at
positive symptoms, negative symptoms and cognitive symptoms which was also further
converted into analysis of variance with P-value. The Dimond study assessed efficacy utilizing
the Wing Symptom Rating and the Behavior Rating Scale at baseline and at conclusion, in which
data was converted into analysis of variance with F-score.
RESULTS
In order to review the studies, the 12th week was chosen as the point of comparison for
the Chouinard and Dimond studies while the closest measured time period was the 8th week for
the Noorbala and Kabes studies. The Chouinard et al study was a double blind RCT that
consisted of 60 elderly patients ranging from 54-80 years old, although only 20 patients were
randomly assigned to 12 weeks of treatment with piracetam and the others to placebo.
Chouinard- specifically shows that with treatment, patients showed improvement in alertness and
reported no withdrawal after discontinued use of the intervention and returned to their original
condition within a month. The Dimond et al study was also a double blind crossover RCT that
consisted of 24 patients ranging from 38-63 years old that participated in the study and was
diagnosed with chronic schizophrenia. Dimond studied piracetam and the general facilitation of
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performances producing fewer errors on this task which involves registering the tactual
experience of number and preserving it in memory for recall. The Noorbala et al study, another
double blind RCT was performed on 34 patients ranging from 18-41 years old and a minimum
score of 30 on the PANSS was required for entry into the study. Noorbala studied piracetam
with haloperidol and placebo with haloperidol and showed significant mean change from
baseline with regards to PANSS. Finally, the Kabes et al study was a controlled clinical study
with 14 participants, of which 11 were diagnosed with schizophrenia and 3 had some atypical
depression symptoms. Kabes study shows there is a positive correlation b/w post treatment
clinical improvement and biochemical levels using piracetam.
The mean change from baseline for improvement in behavior or cognitive functions, illustrated
in Table 2, shows 1.2 for 800mg piracetam TID versus 0.3 for placebo, 29.148 for 800mg (2)
piracetam TID versus 5.742 placebo, 2.610 for 3200mg piracetam versus 0.482 for placebo and
finally 0.729 for 2400mg piracetam versus 0.175 for placebo. All studies show statistically
significant p-values (Table 2) demonstrating efficacy with use of piracetam versus placebo.
Table 2- Efficacy based on mean change in behavior and cognitive functions
Study
Comparison
Mean Change from P-value
Baseline
Chouinard
800mg piracetam TID
1.2
<0.001
10
(1983)
Placebo
0.3
Dimond (1979)12
Noorbala (1999)11
Kabes (1979)13

800mg (2) piracetam TID
Placebo
3200mg piracetam
Placebo
2400mg piracetam
Placebo

29.148
5.742
2.610
0.482
0.729
0.175

0.01
0.01
<0.01

Nguyen, Schizophrenia and Piracetam 8
For analysis purposes, continuous data was converted into dichotomous data in the
Chouinard and Kabes study. Based on the BPRS assessment, the Chouinard study reported 1.2
of patients on 800mg piracetam TID saw improvement in behavior or cognition function as
compared to 0.3 on placebo, yielding a significant p-value <0.001(Table 3). The corresponding
NNT was 1, meaning that for every 1 patient treated with 800mg piracetam TID, 1 will see
improvement as compared to placebo. The Kabes study reported that 0.79 of patients on 800mg
(2) piracetam TID saw improvement versus 0.21 on placebo, yielding a p-value <0.01 with a
NNT of 2, so for every 2 patients treated with 800mg (2) TID piracetam, 1 will see improvement
as compared to placebo.
Table 3- Efficacy based on Brief Psychiatric Rating Scale
Study
Comparison
Improvement RBI
from
baseline
10
Chouinard
800mg piracetam TID
1.2
3.0
Kabes

13

Placebo

0.3

2400mg piracetam

0.79

Placebo

0.21

1.93

ABI

NNT P-value

0.9

1

<0.001

0.52

2

<0.01

Finally, the Dimond study measured efficacy with the Wing Symptom Rating and the
Behavior Rating Scale and used ANOVA to calculate F-score. (Table 4) Patients taking 800mg
piracetam TID versus placebo yielded an F-score of 5.0718 and a p-value 0.01, statistically
significant values, meaning improvement was shown in those taking piracetam versus placebo.
In addition, in the Noorbala study, the PANSS was used to measure efficacy and repeated
measures of ANOVA with a two-tailed post hoc tukey showed a significant effect of protocols
on PANSS total scores with a significant p-value of <0.001.
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Table 4- Efficacy based on ANOVA in behavior and cognitive functions
Study
Comparison
Mean
F-score

P-value

Dimond12

0.01

800mg piracetam TID

29.148

Placebo

5.742

5.0718

With regard to safety or adverse events, it was not addressed any of the studies reviewed.
DISCUSSION
Behavioral and cognitive dysfunction are just some of the very few symptoms
experienced in schizophrenia, however if left untreated, it can be disabling to the patient.
Although comparison of the studies, Table 2, showed statistically significant improvement in
behavioral or cognitive functions with the treatment of piracetam versus a placebo, further
clinical investigation is required to explain the discrepancy between the doses of piracetam in
different individuals as well as what other specific psychotropic agents the patients were taking.
Analysis of the Brief Psychiatric Scale (Table 3) continues to support the efficacy of
piracetam in that there is a significant improvement of behavioral and cognitive functions with
p-values of < 0.001 and NNT of 1 and p-values of <0.01 and NNT of 2. This further
demonstrates that with the addition of piracetam, it is more efficacious than the placebo. Finally,
when evaluating efficacy in the Dimond study, ANOVA was used and calculated an F-score of
5.0718, meaning that of the groups that are different, variance is due to something other than
chance. In this study, the F-score is also significant.
Due to the various discrepancies across all data (the specific dosages of the intervention
and the timeframe/duration of the study and the patient population), it cannot be used to compare
treatments across all studies equally. Therefore, analysis and further larger clinical trials
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regarding optimal dosing is required. Limitations across studies included various discrepancies
such as the different dosages of controlled drug, Piracetam; the various duration of timeframe of
the studies; lack of producibility of whether or not taking the controlled drug was safe or if there
was any side effects. Additional limitations include lack of current published studies, small
sample sizes and discrepancies in the type of patient tested as well as differences in the number
of patients studied, and numerous methods to evaluate the effects of piracetam on behavioral and
cognitive functions in patients with schizophrenia. With all these limitations, there is a
possibility that it may have affected the statistical power of the study to detect significant
treatment differences.
At the present moment, it appears piracetam lacks a future in the United States for its uses as an
adjuvant therapeutic option for schizophrenia because although piracetam has various off-label
uses which makes it appealing to practitioners, the FDA has not approved its use in the United
States.

CONCLUSION
Piracetam is a nootropic drug that can improve mental functions in patients with
schizophrenia, however, based on the analysis of the four trials that were included in this review;
it is inconclusive if the addition of piracetam will safely and effectively improve behavioral or
cognitive functions in patients with schizophrenia. Although there are statistically significant
outcomes, it is unclear whether the results are clinically significant enough to warrant changes to
the management of this disease. Furthermore, future research is warranted since there is lack of
current published studies, small sample sizes, insufficient data illustrating calculations, and
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numerous methods to evaluate the effects of piracetam on behavioral and cognitive functions in
patients with schizophrenia.
In some countries, piracetam is available over the counter and is used outside of a
controlled setting whereas in the United States, it is not FDA approved and therefore not
available. Future research should include whether or not patients have comorbid conditions,
whether or not patients are relapsing, address the optimal dosing schedule for piracetam
administration and if piracetam is used in conjunction with other psychotropics for it to be
uniformed throughout, the season that the patients were treated in, and whether or not the
patient’s improvement is the same in a controlled or uncontrolled environment. Until such
research is performed, determination of its true safety profile cannot be validated.
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